Research Topics
| J BruixSummaryAffiliation: Universitat de Barcelona Country: Spain Publications
| Collaborators
|
Detail Information
Publications
New drugs for the treatment of hepatocellular carcinomaEveline Boucher
BCLC Group, Liver Unit, Hospital Clinic, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, University of Barcelona, Barcelona, Spain
Liver Int 29:148-58. 2009..In the next years, efforts should be directed to identifying genomic and proteomic profiling that will help us to assess the prognosis and to define what treatment benefits whom, ultimately giving way to personalized medicine...
Distinct cellular responses differentiating alcohol- and hepatitis C virus-induced liver cirrhosisSharon L Lederer
Department of Microbiology, University of Washington, Seattle, WA, USA
Virol J 3:98. 2006..Global transcriptional profiling using oligonucleotide microarrays was therefore performed on liver biopsies from patients with cirrhosis caused by either chronic alcohol consumption or chronic hepatitis C virus (HCV)...
Management of hepatocellular carcinomaJordi Bruix
, University of Barcelona, , Barcelona, Spain
Hepatology 42:1208-36. 2005- Chemoembolization for hepatocellular carcinomaJordi Bruix
BCLC Group, Liver Unit, IDIBAPS, Hospital Clinic, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
Gastroenterology 127:S179-88. 2004..The analysis of efficacy in these trials should be adjusted for prognostic factors, such as the presence of symptoms, Child-Pugh class, and segmental vascular invasion... - New aspects of diagnosis and therapy of hepatocellular carcinomaJ Bruix
BCLC Group, Liver Unit, IDIBAPS, Digestive Disease Institute, Hospital Clinic, University of Barcelona, Catalonia, Spain
Oncogene 25:3848-56. 2006..Ongoing research should further advance the time at diagnosis and identify new and effective options targeting molecular pathways governing tumor progression... - Uptake of technetium-99m DISIDA by bone metastasis from a hepatomaF Pons
Nuclear Medicine Service, Hospital Clinic, Barcelona, Spain
Clin Nucl Med 13:280-2. 1988..The use of imaging with biliary tracers can increase the diagnostic specificity when bone metastases from hepatoma are suspected... - Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinomaJ M Llovet
Liver Unit, , , University of Barcelona, Catalonia, Spain
Hepatology 33:1124-9. 2001..Iatrogenic dissemination was related to subcapsular location or an invasive tumoral pattern, and has to be considered when selecting curative treatments for HCC or adjuvant therapies before liver transplantation... - Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?R Vilana
Diagnosis Imaging Center, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain
Eur Radiol 16:2454-62. 2006..The 1-month CEUS has a high diagnostic accuracy compared with spiral-CT in the usual assessment of percutaneous treatment response... - [Early diagnosis of liver cancer]M Sala
, IMD, , Universitat de Barcelona, IDIBAPS, Barcelona, Spain
Gastroenterol Hepatol 28:292-7. 2005..Using this approach, 40-80% of tumors identified are solitary at diagnosis, although only half of these patients can benefit from curative treatment... - Review article: natural history and prognostic prediction of patients with hepatocellular carcinomaM Varela
, Liver Unit IMD, , , University of Barcelona, Catalonia, Spain
Aliment Pharmacol Ther 17:98-102. 2003..To achieve both aims, within the Barcelona Clinic Liver Cancer Group we have developed a staging system that combines prognosis prediction with decision making, thus becoming a useful tool both for practice and research... - Design and endpoints of clinical trials in hepatocellular carcinomaJosep M Llovet
HCC Translational Research Lab, Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Villarroel 170, 08036 Barcelona, Catalonia, Spain
J Natl Cancer Inst 100:698-711. 2008..These surrogate markers may help to enrich study populations and maximize the cost-benefit ratio of trial execution. Design and conduct of phase 3 trials should be coordinated by centers with appropriate expertise in HCC... - Prognosis of hepatocellular carcinomaJosep M Llovet
Barcelona-Clinic Liver Cancer (BCLC) Group, Liver Unit, Institut de Malalties Digestives, , University of Barcelona, Catalonia, Spain
Hepatogastroenterology 49:7-11. 2002..In addition to predicting prognosis, the staging system should also guide the selection of treatment and this is the major advantage of the classification applied in the Barcelona-Clinic Liver Cancer Group... - Current strategy for staging and treatment: the BCLC update and future prospectsAlejandro Forner
Barcelona Clinic Liver Cancer BCLC Group, Liver Unit, ICMDM, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
Semin Liver Dis 30:61-74. 2010..Finally, patients at end-stage should merely receive palliative care... - A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinomaJ M Llovet
BCLC Group, Liver Unit, Digestive Disease Institute, Hospital Clinic, University of Barcelona, Catalonia, Spain
Eur J Cancer 37:1352-8. 2001..In conclusion, oral eniluracil/5-FU had minimal, if any, activity in patients with inoperable HCC, but the safety profile was acceptable... - High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosisM Gimenez-Barcons
Liver Unit, Institut de Malalties Digestives, Departament de Medicina, IDIBAPS, Hospital Clinic, University of Barcelona, Spain
Hepatology 34:158-67. 2001..Therefore, a mutated HCV-PKR-bd phenotype is very common in cirrhotic patients with hepatocellular carcinoma... - Pseudotumoral hepatic tuberculosisM Varela
Liver Unit, Institut de Malaties Digestives, , Villarroel 170, 08036 Barcelona, Spain
J Hepatol 39:654. 2003 - Technetium-99m DISIDA hepatobiliary agent in diagnosis of hepatocellular carcinoma: relationship between detectability and tumor differentiationX Calvet
Liver Unit, Hospital Clinic i Provincial, Barcelona, Spain
J Nucl Med 29:1916-20. 1988..Since its sensitivity is related to the degree of tumor differentiation, it may be indicated when aspiration cytology is unable to distinguish between well differentiated HCC and reactive changes due to hepatic cirrhosis... - Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalJosep M Llovet
Barcelona Clinic Liver Cancer Group, Liver Unit, Digestive Disease Institut, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Catalonia, Spain
Hepatology 37:429-42. 2003..In conclusion, chemoembolization improves survival of patients with unresectable HCC and may become the standard treatment. Treatment with tamoxifen does not modify the survival of patients with advanced disease... - Prognostic assessment and evaluation of the benefits of treatmentJordi Bruix
Barcelona Clinic Liver Cancer Group, Liver Unit, Digestive, Disease Institute, Barcelona, Catalonia Spain
J Clin Gastroenterol 35:S138-42. 2002..Finally, those with severe liver function or health status impairment constitute the end-stage category and cannot be expected to survive more than 1 year... - Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialJosep M Llovet
Liver Unit, Digestive Disease Institute, , University of Barcelona, Barcelona, Spain
Lancet 359:1734-9. 2002..45 [95% CI 0.25-0.81], p=0.02). INTERPRETATION: Chemoembolisation improved survival of stringently selected patients with unresectable hepatocellular carcinoma... - The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinomaJosep M Llovet
Liver Unit, Digestive Disease Institute, IDIBAPS, , University of Barcelona, Catalonia, Spain
Liver Transpl 10:S115-20. 2004..Finally, patients with end-stage disease should receive only palliative treatment to avoid unnecessary suffering... - Prognostic prediction and treatment strategy in hepatocellular carcinomaJordi Bruix
, Liver Unit, Digestive Disease Institute, , Villaroel 170, 08036 Barcelona, Catalonia, Spain
Hepatology 35:519-24. 2002 - Treatment of early hepatocellular carcinoma: Towards personalized therapySilvia Tremosini
BCLC Group, Liver Unit, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona, Spain
Dig Liver Dis 42:S242-8. 2010..We briefly reviewed therapeutic management for early HCC, taking into account that any recommendation should be delivered in the clinical setting and based on an individualised evaluation of each patient... - Selection of candidates with HCC for transplantation in the MELD eraMargarita Sala
Barcelona-Clinic-Liver-Cancer Group, Liver Unit, , University of Barcelona, Barcelona, Spain
Liver Transpl 10:S4-9. 2004..3%. 5. Priority policies have to be developed and refined to provide a fair and effective distribution of cadaveric organs... - Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantationJ M Llovet
Barcelona Clinic Liver Cancer Group, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain
Gut 50:123-8. 2002..Survival after liver transplantation for early hepatocellular carcinoma (HCC) is worsened by the increasing dropout rate while waiting for a donor... - Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinomaMargarita Sala
Liver Unit, , , University of Barcelona, Catalonia, Spain
Hepatology 40:1352-60. 2004..Accordingly, initial complete tumor necrosis should be considered a relevant therapeutic target irrespective of tumor size and liver function... - [Treatment of advanced hepatocellular carcinoma]Alejandro Forner
Unidad de Oncología Hepática BCLC, Servicio de Hepatologia, ICMDM, Hospital Clinic, IDIBAPS, Universidad de Barcelona, Barcelona, Espana
Gastroenterol Hepatol 33:461-8. 2010..The present article provides a review of the treatment of advanced-stage HCC, with special emphasis on the distinct agents that are currently under evaluation... - Treatment of hepatocellular carcinomaAlejandro Forner
Liver Unit, Institut de Malalties Digestives i Metaboliques, BCLC Group, IDIPAPS, Hospital Clinic, University of Barcelona, C/Villarroel 170, E-08036 Barcelona, Spain
Crit Rev Oncol Hematol 60:89-98. 2006..Finally, the patients with severe cancer-related symptoms or great tumor burden belong to the terminal stage and only benefit from symptomatic treatment... - Treatment of hepatocellular carcinoma: is there an optimal strategy?Maria Varela
Barcelona Clinic Liver Cancer Group, Liver Unit, Digestive Disease Institute, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Villarroel 170, Barcelona, Spain
Cancer Treat Rev 29:99-104. 2003..Finally, patients with end-stage disease with heavily impaired liver function (Child-Pugh class C) or severe physical impairment (performance status 3-4) die within 6 months and should receive only symptomatic treatment... - Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokineticsMaria Varela
Liver Unit, IMDM, Barcelona Clinic Liver Cancer BCLC Group, Hospital Clinic, CIBER HEPAD, University of Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer, IDIBAPS, Barcelona, Spain
J Hepatol 46:474-81. 2007..This study assesses the safety, pharmacokinetics and efficacy of transarterial chemoembolization using drug eluting beads (DEB), an embolizing device that slowly releases chemotherapy to decrease systemic toxicity... - Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinomaAlejandro Forner
BCLC Group, Liver Unit, IDIBAPS, CIBERehd, Hospital Clinic, University of Barcelona, Spain
Hepatology 47:97-104. 2008..These results validate the American Association for the Study of Liver Disease (AASLD) guidelines... - p27(Kip1) is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinomaCarolina Armengol
, Liver Unit, Digestive Disease Institute, , , University of Barcelona, Villarroel 170, 08036 Barcelona, Catalonia, Spain
J Hepatol 38:591-7. 2003..015) and microvascular invasion (P=0.016). CONCLUSIONS: p27 underexpression is frequent in relatively early stages of HCC and constitutes an independent predictor of recurrence after surgical resection... - Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinomaJordi Rimola
BCLC Group Radiology Department, Hospital Clinic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Institut d Investigacions Biomédiques August Pi y Sunyer, University of Barcelona, Barcelona, Spain
Hepatology 50:791-8. 2009..If washout is not registered, a biopsy should be mandatory for diagnosis... - MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlationMarta Burrel
Radiology Department, , , University of Barcelona, Catalonia, Spain
Hepatology 38:1034-42. 2003..In conclusion, MRA has a high diagnostic accuracy for HCC > or =10 mm and is more sensitive than triphasic helical CT in nodules sized 10 to 20 mm. MRA is the optimal technique for HCC staging prior to curative therapies... - Prognostic prediction in patients with hepatocellular carcinomaMargarita Sala
Liver Unit, , University of Barcelona, , 08036 Barcelona, Spain
Semin Liver Dis 25:171-80. 2005..It considers tumor stage, liver functional status, physical status, and cancer-related symptoms and, by dividing patients into early, intermediate, advanced, and end-stage categories, provides a link to treatment indication... - Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasoundRamon Vilana
Radiology Department, Barcelona Clinic Liver Cancer BCLC Group, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain
Hepatology 51:2020-9. 2010..CONCLUSION: CEUS should not be used as the sole imaging technique for conclusive hepatocellular carcinoma diagnosis and if the MRI does not display the diagnostic vascular pattern, a confirmatory biopsy is mandatory... - Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinomaAmelia J Hessheimer
BCLC Group, Liver Unit, Hospital Clinic, IDIBAPS, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, University of Barcelona, Catalonia, Spain
Eur J Gastroenterol Hepatol 22:1239-44. 2010..Recent studies have identified cases of hepatocellular carcinoma (HCC) arising in cryptogenic cirrhosis and proposed that many of them may be attributable to nonalcoholic fatty liver disease (NAFLD)... - Orthotopic implantation of human hepatocellular carcinoma in mice: analysis of tumor progression and establishment of the BCLC-9 cell lineCarolina Armengol
BCLC Group, Liver Unit, Digestive Disease Institute, , , Barcelona, Spain
Clin Cancer Res 10:2150-7. 2004..CONCLUSIONS: The orthotopic implantation of early HCC fragments in nude mice provides a useful model to investigate the mechanisms of human HCC evolution and to establish new cell lines... - IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockageVictoria Tovar
HCC Translational Laboratory, BCLC Group, Liver Unit and Pathology Department, Hospital Clinic, CIBERehd, IDIBAPS, C Villarroel 170, Catalonia, Spain
J Hepatol 52:550-9. 2010..We analyzed the underlying molecular mechanisms of IGF signaling activation in early hepatocellular carcinoma (HCC; BCLC class 0 or A) and assessed novel targeted therapies blocking this pathway... - Novel advancements in the management of hepatocellular carcinoma in 2008Josep M Llovet
Barcelona Clinic Liver Cancer BCLC Group, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, CIBERehd, Hospital Clinic, Villarroel 170, 08036 Barcelona, Catalonia, Spain
J Hepatol 48:S20-37. 2008..Now, the research effort faces other areas of unmet need, such as the adjuvant setting of resection/local ablation and combination therapies... - Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?Alejandro Forner
Liver Unit, Barcelona Clinic Liver Cancer BCLC Group, Hospital Clinic, August Pi i Sunyer Institute of Biomedical Investigations, Biomedical Center for Research into Hepatic and Digestive Diseases CIBEREHD, University of Barcelona, Barcelona, Spain
Cancer 115:616-23. 2009..The current report provides an assessment of the agreement/concordance between both RECIST and the EASL guidelines for the evaluation of response to therapy... - Abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients: a randomized controlled studyJosep Fuster
Department of Surgery, Hospital Clinic, University of Barcelona, Spain
Hepatogastroenterology 51:536-40. 2004..The objective of our study is to assess the usefulness of intra-abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients... - Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablationRamon Vilana
Radiology Department, , , University of Barcelona, Calle Villarroel, 170, 08036 Barcelona, Spain
J Clin Ultrasound 31:119-28. 2003..However, although contrast-enhanced PDI may be useful for real-time guidance of treatment, its low sensitivity makes it inadequate to accurately assess the completeness of ablation... - Hepatitis B virus and hepatocellular carcinomaJordi Bruix
BCLC Group, Liver Unit, Digestive Disease Institute, , IDIBAPS, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
J Hepatol 39:S59-63. 2003 - Hepatocellular carcinomaJosep M Llovet
, Liver Unit, Digestive Disease Institute, IDIBAPS, Hospital Cli;nic i Provincial, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain
Lancet 362:1907-17. 2003..Meta-analysis shows that only chemoembolisation improves survival in well-selected patients with unresectable HCC... - Liver transplantation in hepatocellular carcinomaJosep Fuster
Barcelona-Clinic Liver Cancer (BCLC) Group, Department of Surgery, Digestive Disease Institute, , Hospital Clinic, University of Barcelona, Villaroel 170, 08036 Barcelona, Catalonia, Spain
Transpl Int 18:278-82. 2005..The development of adult living donor liver transplantation has proved to be a good alternative in this type of patients even if they do not fulfill the conventional criteria... - Expected developments in hepatologyXavier Forns
Liver Unit, , , University of Barcelona, Spain
Best Pract Res Clin Gastroenterol 16:957-70. 2002..The risk factors and primary, secondary and tertiary prevention of the condition are also analysed. Finally, the development of new therapeutic strategies for hepatocellular carcinoma is evaluated by evidence-based studies... - High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantationMargarita Sala
Liver Unit, , , University of Barcelona, Catalonia, Spain
Liver Transpl 10:1294-300. 2004..In conclusion, this policy is clinically effective and could further improve the outcome of resected patients... - Focus on hepatocellular carcinomaJordi Bruix
BCLC Group, Liver Unit, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
Cancer Cell 5:215-9. 2004 - Angiogenesis in liver diseaseMercedes Fernandez
Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
J Hepatol 50:604-20. 2009.... - Hepatocellular carcinoma in the setting of liver transplantationMaria Varela
, Liver Unit, , , Barcelona, Spain
Liver Transpl 12:1028-36. 2006 - Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiationSigal Kremer Tal
Division of Liver Diseases and Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
J Hepatol 46:645-54. 2007..Hepatocellular carcinoma (HCC) has the most rapidly rising cancer incidence in the US and Europe. The KLF6 tumor suppressor is frequently inactivated in HCC by loss-of-heterozygosity (LOH) and/or mutation... - Sorafenib in advanced hepatocellular carcinomaJosep M Llovet
Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
N Engl J Med 359:378-90. 2008..A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma... - Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decisionJordi Bruix
Liver Transpl 9:700-2. 2003 - Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinomaMaria W Smith
Department of Microbiology, School of Medicine, and Washington National Primate Research Center, University of Washington, Seattle, Washington 98195, USA
Cancer Res 63:859-64. 2003..Thus, high throughput methods coupled with high-order statistical analyses may result in the development of new diagnostic tools for liver malignancies... - Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet thereJosep M Llovet
Mount Sinai Liver Cancer Program, Divisions of Liver Disease and Recanati Miller Transplantation Institute, Department of Surgery, Mount Sinai School of Medicine, New York, NY 10029, USA
Semin Liver Dis 26:248-53. 2006..Only a few small studies with heterogeneous target populations and treatments applied are available. The results of these studies are inconsistent and do not provide compelling evidence to accept down-staging as a standard of care... - Diagnosis and staging of hepatocellular carcinoma prior to transplantation: expertise or failureMaria Varela
Liver Transpl 12:1445-7. 2006 - Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinomaElisa Wurmbach
Mount Sinai Liver Cancer Program, Division of Hematology Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
Hepatology 45:938-47. 2007..CONCLUSION: These findings provide a comprehensive molecular portrait of genomic changes in progressive HCV-related HCC... - A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosisJosep M Llovet
Mount Sinai Liver Cancer Program, Department of Medicine, Mount Sinai School of Medicine, New York 10029, USA
Gastroenterology 131:1758-67. 2006..Small liver nodules approximately 2 cm are difficult to characterize by radiologic or pathologic examination. Our aim was to identify a molecular signature to diagnose early hepatocellular carcinoma (HCC)... - Focal gains of VEGFA and molecular classification of hepatocellular carcinomaDerek Y Chiang
Department of Medical Oncology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, MA 02115, USA
Cancer Res 68:6779-88. 2008..Furthermore, the prevalence of VEGFA high-level gains in multiple tumor types suggests indications for clinical trials of antiangiogenic therapies... - Treatment strategies for hepatocellular carcinoma in cirrhosisW Scott Helton
Department of Surgery, University of Illinois, Chicago, IL, USA
J Gastrointest Surg 7:401-11. 2003 - HCC surveillance: who is the target population?Jordi Bruix
Hepatology 37:507-9. 2003 - Diagnosis of Small HCCJordi Bruix
Gastroenterology 129:1364. 2005 - Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markersMaria W Smith
Department of Microbiology, School of Medicine, University of Washington, Seattle, WA 98195, USA
Hepatology 38:1458-67. 2003..In conclusion, our microarray analysis identified several potential gene markers of HCV-associated liver disease and contributed to our rapidly expanding database of experiments describing HCV pathogenesis... - Molecular targeted therapies in hepatocellular carcinomaJosep M Llovet
Mount Sinai Liver Cancer Program, Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA
Hepatology 48:1312-27. 2008..Ultimately, a molecular classification of HCC based on genome-wide investigations and identification of patient subclasses according to drug responsiveness will lead to a more personalized medicine... - Liver cancer: An evolving challenge reaching research maturityJordi Bruix
Hepatology 47:1103-4. 2008 - Unresectable hepatocellular carcinoma: meta-analysis of arterial embolizationJosep M Llovet
Radiology 230:300-1; author reply 301-2. 2004 - Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinomaSigal Kremer-Tal
Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
Hepatology 40:1047-52. 2004..In conclusion, we propose that KLF6 is deregulated by loss and/or mutation in HCC, and its inactivation may contribute to pathogenesis in a significant number of these tumors... - Clinical management of hepatic malignancies: ferucarbotran-enhanced magnetic resonance imaging versus contrast-enhanced spiral computed tomographyRiccardo Lencioni
Department of Radiology, University of Pisa, Pisa, Italy
Dig Dis Sci 50:533-7. 2005..0167). Ferucarbotran-enhanced MR imaging is superior to spiral CT in clinical management of patients with suspected hepatic malignancy... - Hepatocellular carcinoma in the United States. Lessons from a population-based study in Medicare recipientsMaria Varela
J Hepatol 44:8-10. 2006 - Locoregional treatment for hepatocellular carcinoma: From clinical exploration to robust clinical data, changing standards of careAlejandro Forner
Hepatology 47:5-7. 2008